Dr. Gorantla's Laboratory

Research Goals
Collaborators
Funding
Techniques used in the laboratory
Personnel
Return to Dr. Gorantla's home page
Dr. Gorantla's biographical information
Lab Phone: 402-559-1784


Research Goals


Collaborators

Larisa Poluektova, M.D., Ph.D., UNMC

top of page


Funding

Humanized Mice as a Tool to Monitor of HIV Brain Reservoirs and Effects of Substance Abuse
PI: Gorantla, S.
Source: NIH/NIDA 5R33DA041018
Proposes to adapt a humanized mouse model to validate the role of astrocytes and microglia as HIV reservoir s in the brain. Use of the human IL-34-expressing mouse as a driver for enhanced development and engraftment of human neural progenitor cells into glial and innate human immune cells provides the potential for development of a functional model with which to study HIV reservoirs in the brain and the effect of drugs of abuse.

NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence
PI: H. Gendelman; Animal Core: S. Gorantla
Source: NIH/NIDA 5P01DA028555
This is an integrative cross approach translational and multi-investigator program grant seeking to develop nanoformulated antiretroviral drug therapy from the bench to the patient.

Role of pannexin-1 hemichannels in NeuroAIDS
PI: Gorantla, S.
Source: University of Texas Medical Branch at Galveston

Chronic HIV infection and Aging in NeuroAIDS (CHAIN)Center
MPI: S. Buch and H. Fox; Cell-Tissue-Animal Core Leader: S. Gorantla
Source: NIH/NIMH 3P30MH062261
This is a Center grant to provide Administrative and Core Support for scientists investigating NeuroAIDS.

PDGF-CC Mediated Reversal of Synaptodendritic Injury in HAND
PI: S. Buch; Co-I: S. Gorantla
5R01MH106425
The overarching goal of this application is to explore the role of platelet-derived growth factor (PDGF)-CC in reversing synaptodendritic injury & the associated cognitive decline, both of which comprise the hallmark features of HIV-associated neurocognitive disorders (HAND).  Combinatorial in vitro, in vivo and ex vivo approaches are proposed to test the efficacy of PDGF-CC as a therapeutic agent.

Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
PI: H. Gelbard, University of Rochester;  Co-I: S. Gorantla
NIH/NIMH 5R01 MH104147
This proposal is designed to develop a means to eradicate viral infection from its CNS reservoir. The overarching idea is to facilitate crystalline nano formulated antiretroviral drug entry into monocyte-macrophage within late and recycling endosomes by affecting/harnessing phagolysosomal fusion events through the new kinase inhibitor URMC-099. The research is divided equally amongst University of Nebraska and University of Rochester scientists experienced in virology, immunology, pharmacology and neuroscience to pool resources towards a functional HIV-1 cure.

top of page


Techniques used in the laboratory

top of page


Personnel

Lili Guo
Research Technologist II
 
Li Wu
Research Technologist II
Li Wu

Return to Dr. Gorantla's home page
Dr. Gorantla's biographical information